XenoTech - In Vitro Drug Metabolism & Drug-Drug Interaction Studies, Cytochromes (CYP) P450

Sekisui XenoTech offers unrivaled quality and selection with an extensive array of products to assist all your in vitro ADME research needs. Our standard products feature cellular and subcellular fractions, hepatocytes, tissue samples, media and more from many different toxicologically relevant species. We are the sole North American distributor for cell lines from JCRB, recombinant CYP enzymes, P450 substrates and metabolites from Cypex, and metabolite production kits from HepatoChem. Whatever your in vitro research needs, Sekisui XenoTech can help. Order all your products online in our eStore!

Start shopping now!

At Sekisui XenoTech, we recognize the importance of having readily available, reliable information. Our customers rely both on the quality of our products and on our expertise in biotransformation to help them with their research needs.

Visit our scientific resource center

Sekisui XenoTech's scientific resources as well as cell and tissue-based products stem from our unparalleled global contract research experience and proven expertise from discovery through clinical support.

Explore our contract research services

News and Events

Wednesday, May 6, 2020
Webinar: In Vitro Inhibition Studies - Elements of Design and Important Considerations in Data Analysis

Frequently asked questions about inhibition studies, recommendations for successful regulatory submission, critical considerations in design and more...
Wednesday, September 2, 2020
Webinar - Suicide by Binding: Putting Time-Dependent Inhibition of CYP Enzymes into Perspective

Drug candidates can be screened out in discovery due to a time-dependent cytochrome P450 (CYP) enzyme inhibition signal in an in vitro IC₅₀ shift assay because time-dependent inhibition (TDI) is often of greater clinical concern than direct inhibition. But depending on the drug target or intended indications, this approach may be akin to throwing the baby out with the bathwater. This webinar will take you on a deep-dive into time-dependent inhibition (TDI), exploring in vitro approaches to evaluate time-dependent inhibition, methods to distinguish reversible from irreversible TDI, and approaches to predicting related clinical DDIs...
Tuesday, April 21, 2020
Webinar: Comparing the Final FDA, EMA & PMDA In Vitro DDI Guidance Documents

In January, the FDA published its final guidance for industry on in vitro drug-drug interaction studies. Dr. Ogilvie offers his expert perspective on major changes, whether they will impact your development plans, how the guidance compares with the EMA and PMDA in vitro guidance documents and how to harmonize your drug development strategies to meet the expectations of all three...

Register Now

Register Now

Register Now

Online SOT Presentations

eStore

Resources

News and Events

Webinar: In Vitro Inhibition Studies - Elements of Design and Important Considerations in Data Analysis

Webinar - Suicide by Binding: Putting Time-Dependent Inhibition of CYP Enzymes into Perspective

Webinar: Comparing the Final FDA, EMA & PMDA In Vitro DDI Guidance Documents

Log-In

Register Now

Register Now

Register Now

Online SOT Presentations

eStore

Resources

News and Events

Webinar: In Vitro Inhibition Studies - Elements of Design and Important Considerations in Data Analysis

Webinar - Suicide by Binding: Putting Time-Dependent Inhibition of CYP Enzymes into Perspective

Webinar: Comparing the Final FDA, EMA & PMDA In Vitro DDI Guidance Documents

Newsletter Signup